On August 27-28, the 19th FROST & SULLIVAN Global Growth, Innovation & Leadership Summit and the 4th New Investment Conference were grandly held at the Shanghai Jing'an Shangri-La Hotel.

With its cutting-edge innovation and industry leadership in the field of recombinant collagen, EVERON HEALTHCARE won the "Global Recombinant Collagen Technology Innovation Leadership Award" and became one of the high-profile biotechnology enterprises in this summit.

At the gala dinner, the prestigious 2025 Frost & Sullivan Global Awards for Growth, Innovation & Leadership, China Awards, and Best Practices Awards were unveiled. EVERON HEALTHCARE was honored with the 2025 “Global Innovation Leadership Award for Recombinant Collagen Technology.”

EVERON HEALTHCARE distinguished itself among global competitors with its “recombinant humanized triple-helix collagen” technology system, becoming the sole Chinese enterprise honored in this specialized technical field this year. This accolade underscores international recognition of the company's scientific capabilities and innovative prowess.

During the conference, EVERON HEALTHCARE established a dual exhibition booth at the venue, showcasing its full range of products and technologies. 

The systematic display featured multiple flagship products, including “Recombinant Human-Derived Lyophilized Fibrin” and “Recombinant Human-Derived Triple-Helix Type III Collagen Raw Material.”

These products are based on the company's proprietary high-stability triple-helix collagen technology, which overcomes the technical limitations of traditional animal-derived collagen and demonstrates significant application advantages and development potential.

The EVERON HEALTHCARE booth was bustling with visitors, all gathered to explore the latest frontiers in biotechnology.

Md. Ann Zhang, Chief Technology Officer of the company, attended the New Investment Summit Forum on Life Sciences (Medical Devices Session) and delivered a presentation titled “Technological Innovation and Development of Recombinant Humanized Triple-Helix Collagen and Its Aesthetic Medicine Applications.”

Dr. Ann Zhang shared insights on the breakthroughs and considerations surrounding recombinant humanized triple-helix collagen from multiple perspectives, including technical principles, product development, and industrial implementation.

Meanwhile, EVERON HEALTHCARE and Frost & Sullivan jointly released the Blue Book on the Current Status and Future Trends of the Medical Aesthetics Injection Products Industry by 2025, providing strategic guidance for the sector and driving the standardization and innovative application of collagen-based products.

This award not only signifies international recognition of EVERON HEALTHCARE's current achievements but also serves as a strong endorsement of its ongoing commitment to innovation.